Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR‐TKI Administration Using Droplet Digital PCR in Non‐small‐cell Lung Cancer With EGFR Mutation
Cancer Diagnosis & Prognosis · 03.05.2025 · 5 (3) · 285-299
DOI: 10.21873/cdp.10441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 03.05.2025. Verfasst von Koichi Ogawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/Aim: This study aimed to investigate the effectiveness of sequential treatment with afatinib and osimertinib by clarifying the correlation between therapeutic effects and EGFR T790M mutant allele frequency. Patients and Methods: From August 2013 to July 2019, tumor samples from before and after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) administration were collected from patients from eight institutions. We measured T790M mutant allele frequency using droplet digital polymerase chain reaction using biopsy specimens from patients mainly treated with afatinib and analyzed the T790M to EGFR-activating mutation ratio (T/A ratio) in pre- and post-biopsy tissue.
Results
Among 36 patients (afatinib group: n=24, first-generation EGFR-TKI group: n=12) with preserved pre- and post-biopsy tissue, the median T/A ratios before (pre-T/A ratio) and after EGFR-TKI administration (post-T/A ratio) in the afatinib group were 0.005 and 0.014, and those in the first-generation EGFR-TKI group were 0.026 and 0.352, respectively. The results of a Mann-Whitney U-test revealed that the difference between the pre-T/A and post-T/A ratios was not higher in the afatinib group than in the first-generation EGFR-TKI (p=0.0372). No significant difference in progression-free or overall survival was found between the two groups.
Conclusion
Compared with first-generation EGFR-TKI treatment, treatment with afatinib did not affect changes in the T/A ratio.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
- Watanabe Hospital, Osaka, Japan.
- Department of Clinical Oncology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
- Center for Biomedical Sciences, CIMS, Wakayama Medical University, Wakayama, Japan.
- Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
Zitieren
APA
Ogawa, K., Kaneda, H., Koh, Y., Matsumoto, Y., Sawa, K., Tamiya, M., Ishikawa, N., Minami, K., Suzuki, H., Eguchi, Y., Kanazu, M., Sato, Y., & Kawaguchi, T. (2025). Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR‐TKI Administration Using Droplet Digital PCR in Non‐small‐cell Lung Cancer With EGFR Mutation. Cancer Diagnosis & Prognosis, 5(3), 285-299. https://doi.org/10.21873/cdp.10441
Vancouver
Ogawa K, Kaneda H, Koh Y, Matsumoto Y, Sawa K, Tamiya M, et al. Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR‐TKI Administration Using Droplet Digital PCR in Non‐small‐cell Lung Cancer With EGFR Mutation. Cancer Diagnosis & Prognosis. 2025;5(3):285-299. doi:10.21873/cdp.10441
BibTeX
@article{Ogawa2025,
author = {Ogawa, Koichi and Kaneda, Hiroyasu and Koh, Yasuhiro and Matsumoto, Yoshiya and Sawa, Kenji and Tamiya, Motohiro and Ishikawa, Nobuhisa and Minami, Kenichi and Suzuki, Hidekazu and Eguchi, Yosuke and Kanazu, Masaki and Sato, Yuki and Kawaguchi, Tomoya},
title = {Relationship Between T790M Allele Frequency and Therapeutic Effects Before and After EGFR‐TKI Administration Using Droplet Digital PCR in Non‐small‐cell Lung Cancer With EGFR Mutation},
journal = {Cancer Diagnosis & Prognosis},
year = {2025},
volume = {5},
number = {3},
pages = {285--299},
doi = {10.21873/cdp.10441}
}
EUVIMED